RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 FCR Superior in Treatment of Advanced CLL
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 16
OP 16
DO 10.1177/1559897715570605
UL http://mdc.sagepub.com/content/14/55/16.1.abstract
AB Bendamustine plus rituximab is inferior to fludarabine plus cyclophosphamide plus rituximab in treatment of chronic lymphocytic leukemia. The triple-drug combination is associated with improved outcomes but higher rates of neutropenia and severe infection. The triple combination remains the standard therapy in fit patients, with the double combination being an option for elderly patients.